Print

California Stem Cell, Inc. Files IND to Commence Phase I Clinical Trial in Spinal Muscular Atrophy  
12/1/2010 10:33:51 AM

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that CSC has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I.
//-->